Economic evaluation of bivalirudin with provisional glycoprotein IIB/IIIA inhibition versus heparin with routine glycoprotein IIB/IIIA inhibition for percutaneous coronary intervention Results from the REPLACE-2 trial by Cohen, David J. et al.
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OBJECTIVES The purpose of this study was to compare the cost of percutaneous coronary intervention
(PCI) using bivalirudin with provisional platelet glycoprotein (GP) IIb/IIIa inhibition with
that of heparin  routine GP IIb/IIIa inhibition.
BACKGROUND Although GP IIb/IIIa inhibition has been shown to reduce ischemic complications in a broad
range of patients undergoing PCI, many patients currently do not receive such therapy
because of concerns about bleeding complications or cost. Recently, bivalirudin with
provisional GP IIb/IIIa inhibition has been validated as an alternative to heparin  routine
GP IIb/IIIa inhibition for patients undergoing PCI. However, the cost-effectiveness of this
novel strategy is unknown.
METHODS In the Randomized Evaluation in PCI Linking Angiomax to Reduced Clinical Events
(REPLACE)-2 trial, 4,651 U.S. patients undergoing non-emergent PCI were randomized to
receive bivalirudin with provisional GP IIb/IIIa (n  2,319) versus heparin  routine GP
IIb/IIIa (n  2,332). Resource utilization data were collected prospectively through 30-day
follow-up on all U.S. patients. Medical care costs were estimated using standard methods
including bottom-up accounting (for procedural costs), the Medicare fee schedule (for
physician services), hospital billing data (for 2,821 of 4,862 admissions), and regression-based
approaches for the remaining hospitalizations.
RESULTS Among the bivalirudin group, 7.7% required provisional GP IIb/IIIa. Thirty-day ischemic
outcomes including death or myocardial infarction were similar for the bivalirudin and GP
IIb/IIIa groups, but bivalirudin resulted in lower rates of major bleeding (2.8% vs. 4.5%, p 
0.002) and minor bleeding (15.1% vs. 28.1%, p  0.001). Compared with routine GP
IIb/IIIa, in-hospital and 30-day costs were reduced by $405 (95% confidence interval [CI]
$37 to $773) and $374 (95% CI $61 to $688) per patient with bivalirudin (p  0.001 for
both). Regression modeling demonstrated that, in addition to the costs of the anticoagulants
themselves, hospital savings were due primarily to reductions in major bleeding (cost savings
 $107/patient), minor bleeding ($52/patient), and thrombocytopenia ($47/patient).
CONCLUSIONS Compared with heparin  routine GP IIb/IIIa inhibition, bivalirudin  provisional GP
IIb/IIIa inhibition resulted in similar acute ischemic events and cost savings of $375 to
$400/patient depending on the analytic perspective. (J Am Coll Cardiol 2004;44:
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.05.0851792–800) © 2004 by the American College of Cardiology Foundation
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sver the past decade, numerous clinical trials have demon-
trated that the combination of an intravenous platelet
lycoprotein (GP) IIb/IIIa inhibitor and low-dose unfrac-
ionated heparin leads to substantial reductions in peripro-
edural ischemic complications compared with unfraction-
ted heparin alone in patients undergoing percutaneous
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004, accepted May 11, 2004.oronary intervention (PCI) (1–3). Although the data are
omewhat less definitive, several recent meta-analyses sug-
est that such therapy improves long-term survival as well
See page 1809
4,5). Nonetheless, many PCI patients both in the U.S. and
orldwide do not receive a GP IIb/IIIa inhibitor, in part,
wing to concerns about bleeding complications and cost.
Recently, the direct thrombin inhibitor, bivalirudin, has
een shown to result in rates of ischemic complications
imilar to those with heparin  GP IIb/IIIa inhibition in a
ulticenter clinical trial of more than 6,000 PCI patients
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November 2, 2004:1792–800 Cost-Effectiveness of Bivalirudin for PCI6). In this trial, bivalirudin was associated with a non-
ignificant increase in ischemic events (primarily non–Q-
ave myocardial infarctions [MIs]) and a significant reduc-
ion in protocol-defined major and minor bleeding. The net
mpact of these two effects on overall medical care costs is
nknown. Given the large number of angioplasty proce-
ures performed in the U.S. (currently estimated at 1
illion/year) (7), even modest cost savings on a per patient
asis have the potential to result in substantial savings to the
ealth care system. Therefore, we performed a prospective
conomic evaluation in conjunction with the Randomized
valuation in PCI Linking Angiomax to Reduced Clinical
vents (REPLACE)-2 trial. The objectives of the study
ere: 1) to compare the in-hospital and 30-day costs of PCI
sing bivalirudin  provisional GP IIb/IIIa inhibition with
hose of PCI using the standard anticoagulation regimen of
eparin  routine GP IIb/IIIa inhibition, and 2) to explore
he impact of both ischemic and bleeding complications on
he cost of PCI in contemporary practice.
ETHODS
atient population and treatment protocol. Between
ctober 2001 and August 2002, 6,010 patients undergoing
on-emergent PCI were enrolled in the REPLACE-2 trial.
s specified in the study protocol, the economic analysis
as confined to those patients enrolled at U.S. treatment
ites (n  4,651). Details of the study design have been
escribed previously (6). Patients were eligible if they were
ndergoing PCI with an approved device. Key exclusion
riteria included: ongoing acute MI; recent receipt of one of
he study drugs or low-molecular-weight heparin; or need
or concomitant warfarin therapy. Patients were also ex-
luded if they had a platelet count 100,000, serum
reatinine 4.0 mg/dl, or were at increased risk of bleeding
omplications. The study protocol was approved by the
nstitutional review board at each site, and each patient
rovided informed consent before enrollment.
Patients were randomized in a double-blind, triple-
ummy fashion to treatment with bivalirudin  provisional
P IIb/IIIa inhibition or heparin  routine GP IIb/IIIa
nhibition. Randomization was stratified by study site and
y the operator’s intent to use either abciximab or eptifi-
atide as the GP IIb/IIIa inhibitor. Bivalirudin was admin-
Abbreviations and Acronyms
CABG  coronary artery bypass graft surgery
CI  confidence interval
CK-MB  creatine kinase-MB fraction
GP  glycoprotein
MI  myocardial infarction
PCI  percutaneous coronary intervention
REPLACE  Randomized Evaluation in PCI Linking
Angiomax to Reduced Clinical Eventsstered as a 0.75 mg/kg bolus followed by a 1.75 mg/kg/h infusion for the duration of the PCI procedure. Patients
ould receive up to 4 h of prolonged bivalirudin infusion at
he completion of the PCI procedure at the operator’s
iscretion. Heparin was administered as a 65 U/kg bolus.
dditional boluses of bivalirudin or heparin were given as
eeded to maintain an activated clotting time 225 s.
bciximab and eptifibatide were administered using the
ood and Drug Administration-approved doses for each
ith infusion durations of 12 and 18 h, respectively (2,3).
rovisional GP IIb/IIIa inhibition (or matching placebo for
atients already receiving such therapy) was given at the
perator’s discretion to treat potential thrombotic compli-
ations. All patients received aspirin before PCI, and
retreatment with clopidogrel (300 mg) was strongly en-
ouraged. After PCI, all patients received aspirin  clopi-
ogrel (75 mg/day) for at least 30 days.
ssessment of in-hospital outcomes and clinical follow-up.
aseline characteristics, procedural details, and clinical out-
omes during the initial hospitalization and 30-day
ollow-up period were recorded on standardized case report
orms. Myocardial infarction was defined as either develop-
ent of new, pathologic Q waves; elevation of creatine
inase, MB fraction (CK-MB) to 3 the upper limit of
ormal within 48 h of PCI; or elevation of CK-MB to2
he upper limit of normal at any other time during follow-
p. Major bleeding was defined as any intracranial or
etroperitoneal hemorrhage, clinically overt blood loss re-
ulting in a3 g/dl decrease in hemoglobin, any decrease in
emoglobin 4 g/dl, or transfusion of 2 U of packed red
ells (6). Minor bleeding was defined as any other clinically
vert blood loss that did not meet criteria for major
leeding.
etermination of medical care costs. Medical care costs
or the initial hospitalization and for the 30-day follow-up
eriod were assessed from a societal perspective using a
ombination of “bottom-up” and “top-down” methods as
reviously described (8).
ARDIAC CATHETERIZATION LABORATORY COSTS. De-
ailed resource utilization was recorded for each procedure,
nd the cost of each item was estimated on the basis of the
ean hospital acquisition cost for the item in 2002. Costs
or study drugs (bivalirudin, abciximab, eptifibatide) were
ased on the measured bolus and infusion volumes for each
nd current average wholesale prices, assuming that partially
nused vials would be discarded. Costs of additional dis-
osable equipment, overhead, and depreciation for the
ardiac catheterization laboratory were estimated on the
asis of the average cost per procedure at Beth Israel
eaconess Medical Center in 2002 and adjusted for actual
rocedure duration.
THER HOSPITAL COSTS. All other hospital costs were
etermined using “top-down” accounting methods based on
ach hospital’s Medicare cost report (8). For 2,500 ran-
omly selected patients, itemized bills were obtained for the
nitial hospitalization and any subsequent cardiovascular
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Cost-Effectiveness of Bivalirudin for PCI November 2, 2004:1792–800ospitalizations during the follow-up period. In addition,
e obtained billing data on all patients who experienced a
ajor in-hospital complication. Overall, billing data were
ollected for 2,821 of 4,862 hospital admissions during the
0-day study period. Hospital costs were determined by
ultiplying itemized hospital charges by the cost-center
pecific cost-to-charge ratio obtained from the hospital’s
edicare cost report as previously described (9,10).
For those admissions for which billing data were not
ollected (n  2,041), non-procedural hospital costs were
mputed on the basis of a linear regression model developed
sing the hospital admissions for which complete billing
nformation was available. Independent variables for this
odel included length of stay, intensive care unit length of
tay, ischemic complications, bleeding complications, and
evascularization procedures (model R2  0.74).
THER COSTS. Physician’s fees for inpatient services, major
ardiac procedures, and surgical procedures were based on
he 2002 Medicare Fee Schedule. Costs for outpatient
edical services and medications were not assessed.
tatistical analysis. The prespecified primary end point of
he economic study was total 30-day costs. In addition, a
econdary end point of index hospital costs was examined to
onsider the perspective of a typical hospital that is reim-
ursed for each episode of care. To reduce the impact of
igh cost outliers on group means, the protocol specified
hat 30-day costs greater than the 99th percentile for each
reatment group were assigned costs equal to the 99th
ercentile for the group. Discrete data are reported as
requencies; continuous data are reported as mean  SD.
ost data are reported as both mean and median values.
iscrete variables were compared by Fisher exact test.
ormally distributed continuous variables were compared
y Student t test. Cost and length of stay data were
ompared by the Wilcoxon rank-sum test. All statistical
nalyses were performed according to the intention-to-treat
rinciple.
Multiple linear regression was performed to identify
ndependent predictors of initial hospital costs. Candidate
ariables for this analysis included patient characteristics,
schemic complications, repeat procedures, and bleeding
omplications. Because the goal of this analysis was explan-
tory rather than predictive, length of stay variables were not
onsidered. Untransformed cost was used as the dependent
ariable for these analyses for ease of interpretation and
ecause model fit did not improve appreciably using log-
ransformed costs. Attributable costs were calculated by
ultiplying the independent cost of each event (derived
rom the regression model) by its frequency in the treatment
roup. The absolute cost savings associated with prevention
f specific clinical events were estimated by multiplying the
ndependent cost of each event by the difference in event
requency between the bivalirudin and heparin  GP
Ib/IIIa groups. tESULTS
atient population. Baseline characteristics of the two
reatment groups were generally well-matched (Table 1).
he mean age was 63  11 years. Approximately 30% were
iabetic, 20% had undergone previous coronary artery by-
ass graft surgery (CABG), and more than one-third had
ndergone previous PCI. There was a modest excess of
atients who underwent multivessel PCI in the bivalirudin
roup (17.3% vs. 14.6%, p  0.01). Approximately 60% of
atients in both groups were preselected for eptifibatide as
he GP IIb/IIIa inhibitor, and 87% of patients underwent
tent placement.
rocedural resource utilization and cost. Table 2 sum-
arizes resource utilization and cost for the initial PCI
rocedures. The major difference in resource utilization
etween the two groups was related to procedural antico-
gulants. In the bivalirudin group, 26.9% of patients re-
uired 1 vial of bivalirudin, and mean use was 1.35 vials.
n addition, 7.7% of patients assigned to bivalirudin received
GP IIb/IIIa inhibitor on a provisional basis. Among the
eparin  GP IIb/IIIa group, patients selected for abcix-
mab required an average of 3.37 vials/patient, whereas
hose patients selected for eptifibatide required an average of
.73 vials/patient. Overall, anticoagulant costs were reduced
y approximately $400/patient for the bivalirudin group
ompared with the heparin  GP IIb/IIIa group (95%
onfidence interval [CI] $373 to $431; p  0.001). This
ifference was substantially greater for those patients se-
ected for abciximab (mean difference $848, 95% CI $803 to
894) versus those selected for eptifibatide (mean difference
106, 95% CI $85 to $128).
There was a trend toward increased stent use in the
ivalirudin group compared with the heparinGP IIb/IIIa
roup (1.36 vs. 1.31, p 0.13). This trend was explained by
able 1. Baseline Clinical and Treatment Characteristics
Bivalirudin
Group
(n  2,319)
Heparin 
GP IIb/IIIa Group
(n  2,332)
ge (yrs) 63  11 63  11
ender (% male) 72.7 72.8
iabetes mellitus (%) 29.5 28.1
moking in last 12 months (%) 26.2 24.7
revious myocardial infarction (%) 36.3 35.6
revious CABG (%) 20.0 21.3
revious PCI (%) 37.3 37.6
ultivessel PCI (%) 17.3* 14.6
VG PCI (%) 6.5 7.1
respecified GP IIb/IIIa inhibitor
Eptifibatide (%) 60.2 60.1
Abciximab (%) 39.8 39.9
evice selection
Stent (%) 86.9 86.5
Atherectomy (%) 4.2 4.3
p  0.05 versus heparin  GP IIb/IIIa; all other comparisons p  NS.
CABG  coronary artery bypass graft surgery; GP  glycoprotein; PCI 
ercutaneous coronary intervention; SVG  saphenous vein graft.he imbalance in multivessel PCI procedures between the
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n mean stent use among patients undergoing single-vessel
CI (1.19 vs. 1.18, p  0.98) or multivessel PCI (2.23 vs.
.21, p 0.55). There were no significant differences in any
ther resource measures between the two groups. Total
osts for the index revascularization procedure were reduced
Table 2. Procedural Resource Utilization and C
Bivaliru
Group
Procedure duration (min) 69 5
Contrast volume (ml) 209 1
Balloons (n) 1.27  1
Stents (n) 1.36  1
Guide wires (n) 1.60  1
Guiding catheters (n) 1.56 1
Bivalirudin use
Number of vials 1.35  0
1 vial used (%) 26.9%
GP IIb/IIIa inhibitor use
Provisional GP IIb/IIIa (%) 7.7%
Abciximab vials* 0.30 0
Eptifibatide vials† 0.34 1
Costs
All anticoagulants $530 4
Bivalirudin $453 2
Abciximab* $130 $
Eptifibatide† $42 $
Devices $2,075 1
Supplies $715 2
Room/overhead $1,162 4
Non-physician personnel $123 5
Total index procedure cost $4,606  1,916
*Among patients preselected for abciximab (n  1,949). †A
brackets are medians.
GP  glycoprotein.
Table 3. Initial Hospital Outcomes, Resource
Bivalirudin
Group
Death (%) 0.04
Non-fatal MI (%)
Any 7.2
CK-MB 3–5 2.7
CK-MB 5–10 2.7
CK-MB 10 1.6
Repeat revascularization (%)
Any 1.6
PCI 0.8
CABG 0.9
Bleeding complication (%)
Major bleed 2.8
Minor bleed 15.1
Length of stay (days) 2.0  2.3 [1]
ICU length of stay (days) 0.5  1.1 [0]
Medical costs
Initial procedure $4,606 1,916 [
Repeat procedures $81 547 [$0
Hospital room/ancillary $3,655 5,295 [
Doctor fees $2,220 $810 [$
Total $10,561 6,267 [
Values in brackets are medians.
CABG coronary artery bypass graft surgery; CK-MB creatin
care unit; MI  myocardial infarction; PCI  percutaneous corony $335/patient in the bivalirudin group versus the GP
Ib/IIIa group (95% CI $229 to $441, p  0.001).
nitial hospital outcomes, resource utilization, and costs.
able 3 summarizes initial hospital outcomes for the two
reatment groups. Consistent with the results of the overall
rial, there was no significant difference in the combined
Heparin  GP IIb/IIIa
Group p Value
68  54 0.52
208 119 0.84
1.24 1.05 0.39
1.31 0.96 0.13
1.57 1.03 0.33
1.55 1.11 0.86
0 0 0.001
0% 0.001
0% 0.001
3.37 1.08 0.001
4.73 1.35 0.001
$932 545 0.001
$0 0 0.001
$1,467 466 0.001
$580 183 0.001
$2,024 1,257 0.38
$709 236 0.30
$1,153 482 0.61
$122 54 0.61
41]‡ $4,941 1,793 [$4,603]‡ 0.001
patients preselected for eptifibatide (n  2,792). ‡Values in
ation, and Cost
Heparin  GP IIb/IIIa
Group p Value
0.34 0.04
6.3 0.27
2.8 0.69
1.8 0.03
1.5 0.82
1.3 0.40
0.8 0.87
0.6 0.23
4.5 0.002
28.1 0.001
2.1  2.6 [1] 0.54
0.5  1.4 [0] 0.45
1] $4,941 1,793 [$4,603] 0.001
$80 593 [$0] 0.83
3] $3,725 5,586 [$2,374] 0.39
] $2,221 825 [$2,042] 0.41
6]* $10,966 6,524 [$9,616]* 0.001ost
din
5
19
.07
.00
.05
.10
.89
.99
.26
45
99
432
156
,399
38
96
6
[$4,1
mongUtiliz
$4,14
]
$2,26
2,042
$9,13e kinase-MB fraction; GP glycoprotein; ICU intensive
ary intervention.
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Cost-Effectiveness of Bivalirudin for PCI November 2, 2004:1792–800ncidence of death or MI between the bivalirudin and
eparin  GP IIb/IIIa groups (7.3% vs. 6.6%). However,
ivalirudin  provisional GP IIb/IIIa inhibition was asso-
iated with a significant and consistent reduction in bleed-
ng complications compared with heparin  routine GP
Ib/IIIa inhibition. Protocol-defined major bleeding was
educed by 38% (2.8% vs. 4.5%, p 0.002), minor bleeding
as reduced by 46% (15.1% vs. 28.1%, p  0.001), and
hrombocytopenia (defined as any platelet count 100,000/
l) was reduced by 54% (0.7% vs. 1.5%, p  0.01).
There was a modest trend toward lower hospital room
nd ancillary costs in the bivalirudin group compared with
he heparin  GP IIb/IIIa group ($3,655 vs. $3,725, p 
.38). There were no important differences in repeat pro-
edure costs or physician fees between the two treatment
roups, however. When combined with the lower costs for
he initial revascularization procedures, initial hospital costs
igure 1. Stratified analyses of aggregate 30-day costs by treatment group
ifference in costs between the bivalirudin  provisional glycoprotein (GP)
Table 4. Follow-up Events, Resource Utilizatio
Biv
G
Events between discharge and 30 days
Death (%)
Myocardial infarction (%)
Repeat hospitalization (%)
CABG (%)
PCI (%)
Diagnostic catheterization (%)
Follow-up costs $488
Total costs (study entry to 30 days) $10,868 
Values in brackets are medians. *Total costs do not equal th
costs were trimmed at the 99th percentile for each group.
CABG  coronary artery bypass surgery; GP  glycoprohe associated 95% confidence interval (bars). There was no evidence of heterogen
0.05).ere reduced by an average of $405 per patient with
ivalirudin compared with standard anticoagulation (95%
I $37 to $773, p  0.001).
ollow-up resource utilization and costs. Between hos-
ital discharge and 30-day follow-up, there were no signif-
cant differences in clinical outcomes or resource utilization
etween the two treatment groups (Table 4). As a result,
ollow-up medical care costs were generally similar for the
wo groups, and aggregate 30-day costs remained $374/
atient lower for the bivalirudin group compared with the
eparin  GP IIb/IIIa group (95% CI $61 to $688, p 
.001).
ubgroup analyses. Prespecified subgroup analyses accord-
ng to gender, age, and the presence of an acute coronary
yndrome (defined as unstable angina within 48 h or MI
ithin 7 days of PCI) failed to reveal any significant
nteractions between baseline patient characteristics and the
ding to prespecified patient characteristics. The graph indicates the mean
IIa and heparin  routine GP IIb/IIIa groups (black squares) along with
d Cost
in Heparin  GP IIb/IIIa
Group p Value
0.1 1.00
0.5 0.85
8.5 0.42
0.2 0.58
0.8 0.28
2.2 0.39
[$0] $441 2,586 [$0] 0.62
[$9,321]* $11,242 5,420 [$9,774]* 0.001
of initial hospital costs and follow-up costs because 30-day
PCI  percutaneous coronary intervention.accor
IIb/In, an
alirud
roup
0.1
0.6
7.8
0.3
0.5
2.6
2,829
5,479
e sumeity of treatment effect across any of the subgroups (p value for interaction
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November 2, 2004:1792–800 Cost-Effectiveness of Bivalirudin for PCIagnitude of cost savings seen with bivalirudin (Fig. 1).
he extent of cost savings among patients selected for
ptifibatide as the comparison GP IIb/IIIa inhibitor was
omewhat less than among those patients selected for
bciximab ($185 vs. $559/patient); however, there was no
vidence of statistical heterogeneity of the treatment effect
n cost between subgroups (p value for interaction  0.37).
mong patients who underwent single-vessel PCI (n 
,906), bivalirudin reduced 30-day costs by $401/patient
ompared with $506/patient for those who underwent
ultivessel PCI (n  739).
eterminants of hospital cost. Independent predictors of
nitial hospital cost (exclusive of study drug costs) are
isplayed in Table 5. Repeat revascularization procedures
in-hospital CABG, repeat PCI) were the strongest corre-
ates of in-hospital cost. Among procedural complications,
ajor bleeding, thrombocytopenia, and large periprocedural
I (CK-MB10 upper limit of normal) had the greatest
ndependent impact on cost, whereas small-to-moderate
ost-procedure MI and minor bleeding had lesser impacts.
everal baseline patient characteristics, including the need
or multivessel PCI, acute coronary syndrome presentation,
nd a history of congestive heart failure, were also associated
ith higher initial hospital costs.
Attributable cost calculations indicated that adverse out-
omes accounted for $907 of the initial hospital cost for the
eparin  GP IIb/IIIa group (9% of total hospital cost)
Table 5). The complications with the largest individual
ontributions to hospital cost included major bleeding,
n-hospital CABG, minor bleeding, and thrombocytopenia.
omparison of event-related costs between the bivalirudin
nd heparinGP IIb/IIIa groups indicated that reductions
n major bleeding accounted for $107/patient in hospital
ost savings with bivalirudin, whereas reductions in throm-
able 5. Multivariable Linear Regression Model of Initial Hospit
Factor
Estimated
Cost*
Incidence in Heparin
GP IIb/IIIa Grou
vents
In-hospital CABG $29,506 0.56%
Repeat PCI $8,187 0.77%
Major bleed $6,300 4.46%
Thrombocytopenia $5,842 1.50%
MI (CK-MB 10) $4,084 1.54%
Diagnostic catheterization $2,446 2.66%
MI (CK-MB 5–10) $2,233 1.76%
MI (CK-MB 3–5) $1,165 2.83%
Minor bleed $396 28.13%
atient characteristics
Multivessel PCI $1,710 14.60%
ACS $1,534 23.10%
History of CHF $1,165 6.60%
otal for events
Estimated cost of each complication derived from linear regression model of initial
Difference in incidence between groups statistically significant (p  0.05).
ACS  acute coronary syndrome; CABG  coronary artery bypass graft surg
lycoprotein; MI  myocardial infarction.ocytopenia and minor bleeding accounted for savings of i47 and $52 per patient, respectively. These savings were
artially counterbalanced by increased costs of $87/patient
ue to bypass surgery and $21/patient due to the higher
ncidence of moderate-sized MIs in the bivalirudin group.
inally, $46/patient of excess cost for the bivalirudin group
as attributable to the baseline imbalance in multivessel
CI procedures between the two groups. Overall, differ-
nces in hospital outcomes accounted for $84/patient in cost
avings between the two groups (21% of the observed
ifference). When the analysis was restricted to those
utcomes that differed significantly between the two groups
major bleeding, thrombocytopenia, moderate-sized MI,
nd minor bleeding), event-related cost savings with biva-
irudin increased to $185/patient (in addition to differences
n study drug costs).
The impact of reduced complications on in-hospital costs
as particularly important among the subgroup of patients
or whom eptifibatide was selected as the GP IIb/IIIa
nhibitor. Among this large subset (n  2,792), differences
n in-hospital complications actually accounted for cost
avings of $132/patient—71% of the observed cost savings
n the subgroup. On the other hand, among those patients
reselected for abciximab, differences in in-hospital compli-
ations only accounted for $26/patient in cost savings—
5% of the observed reduction in 30-day costs for this
ubgroup.
ISCUSSION
n the REPLACE-2 trial, a strategy of bivalirudin with
rovisional GP IIb/IIIa inhibition led to similar in-hospital
nd 30-day outcomes among patients undergoing contem-
orary PCI procedures compared with the standard antico-
gulation regimen of heparin with routine GP IIb/IIIa
osts
Incidence in
Bivalirudin
Group
Attributable cost in
Heparin 
GP IIb/IIIa Group
Net Cost Difference
Associated With
Bivalirudin
0.86% $165 $87
0.82% $63 $4
2.76%† $281 ($107)†
0.69%† $88 ($47)†
1.64% $63 $4
2.98% $64 $8
2.72%† $39 $21†
2.67% $33 ($2)
15.05%† $111 ($52)†
17.30%† $206 $46†
22.70% $354 ($6)
7.30% $77 $8
$907 ($84)
tal costs (model R2  0.46). All coefficients were significant at the p  0.05 level.
HF  congestive heart failure; CK-MB  creatine kinase-MB fraction; GP al C

p
hospinhibition (6). Because these outcomes met prespecified
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Cost-Effectiveness of Bivalirudin for PCI November 2, 2004:1792–800tatistical criteria for non-inferiority, a prospective economic
ubstudy was performed to determine which treatment
trategy might be preferred on economic grounds. In our
conomic substudy of more than 4,600 U.S. patients,
linical outcomes were similar to those observed in the
verall trial, whereas economic outcomes favored the biva-
irudin  provisional GP IIb/IIIa group. The absolute
agnitude of cost savings ranged from $405/patient during
he initial hospitalization period to $374/patient over the
ntire 30-day follow-up period and was consistent across a
ariety of prespecified patient subsets.
The reduction in initial hospital costs with bivalirudin
as driven by two main factors: the anticoagulants them-
elves and periprocedural complications. Approximately
0% of the reduction in in-hospital costs occurred during
he index revascularization procedure owing to the lower
cquisition cost of bivalirudin compared with parenteral GP
Ib/IIIa inhibitors. Importantly, these savings were observed
espite the fact that 7% of patients assigned to bivalirudin
eceived a provisional GP IIb/IIIa inhibitor at the time of
CI. The remaining 20% of hospital cost savings associated
ith bivalirudin were related to differences in rates of
schemic and hemorrhagic complications. Although biva-
irudin was associated with marginally higher rates of
n-hospital bypass surgery and non-fatal MI, the excess
osts of these events were more than offset by savings
ssociated with lower rates of major bleeding, minor bleed-
ng, and thrombocytopenia. The impact of reduced compli-
ations on in-hospital costs was particularly important
mong the subgroup of patients for whom eptifibatide was
elected as the comparison GP IIb/IIIa inhibitor. For this
ubgroup, differences in in-hospital complications actually
ccounted for more than 70% of the observed cost savings
ith bivalirudin.
In addition to quantifying the extent of cost savings
ssociated with the use of bivalirudin, this study adds
mportantly to our understanding of those factors that
etermine the cost of contemporary PCI. On a “per
vent” basis, the most costly complications were the need
or unplanned bypass surgery or repeat PCI before
ospital discharge. On the other hand, when the fre-
uency of complications was also considered, the most
ostly complications on a “per patient” basis were major
leeding (attributable cost $342/patient in the heparin 
P IIb/IIIa group), minor bleeding ($151/patient), and
n-hospital bypass surgery ($150/patient). Although the
efinition of major bleeding used in the REPLACE-2
rial was somewhat more liberal than that used in
revious trials, the substantial cost of major bleeding on
oth a per event and per patient basis confirms that this
efinition has both clinical and economic relevance in
ontemporary practice.
Previous studies have demonstrated the important impact
f both ischemic and bleeding complications on hospital
ost for PCI patients. In a single-center study of more than
,200 patients, Ellis et al. (11) found that the strongest andependent predictors of hospital cost were urgent bypass
urgery, blood product transfusion, and acute renal failure.
n the economic analysis of the Evaluation of c7E3 for the
revention of Ischemic Complications (EPIC) trial, the
ncremental costs of repeat revascularization ranged from
4,973/event for non-urgent repeat PCI to $27,349/event
or urgent CABG (12), whereas bleeding costs ranged from
1,327/event for minor bleeding to $5,896/event for major
leeding (using somewhat different definitions than in the
urrent trial). Similar findings were reported in the Evalu-
tion of PTCA to Improve Long-term Outcome by c7E3
P IIb/IIIa receptor (abciximab) blockade (EPILOG) and
andomized Efficacy Study of Tirofiban for Outcome and
estenosis (RESTORE) trials as well (13,14).
Although our findings are qualitatively similar to many
revious studies, the current study is the first to directly
xamine hospital costs and their determinants in a large
opulation of patients undergoing contemporary PCI with
tent implantation. Compared with previous studies from
he balloon angioplasty era, the contribution of ischemic
omplications to in-hospital costs of PCI has fallen dramat-
cally. For example, in the EPIC trial, complications in-
reased initial hospital costs by $2,000/patient in the
ontrol group, of which ischemic complications accounted
or 80% (12). In contrast, in the REPLACE-2 trial, the
ggregate cost of complications was $1,000/patient, of
hich ischemic events accounted for less than 40%. These
ndings reflect a shift in the predominant mode of ischemic
omplications from abrupt closure requiring repeat revascu-
arization to non-fatal MI—many of which are clinically
ilent. As a result, more than 60% of complication-related
osts are now associated with hemorrhagic events and
elated outcomes (e.g., thrombocytopenia). Also noteworthy
s the substantial cost associated with even minor bleeding
omplications. Although these events are associated with
nly a modest increase in costs on a per event basis, the fact
hat more than 25% of all patients treated with the heparin
GP IIb/IIIa inhibition experienced a minor bleed led to
ubstantial excess costs in the overall population.
ractice implications. Our study has important implica-
ions for the selection of a periprocedural anticoagulation
egimen in patients undergoing non-emergent PCI. Previ-
us economic evaluations have demonstrated that heparin
outine GP IIb/IIIa inhibition is reasonably cost-effective
ompared with heparin alone for patients undergoing PCI
ith stent placement, whether the GP IIb/IIIa inhibitor is
bciximab or eptifibatide (15,16). Given the lower cost and
imilar clinical outcomes obtained with bivalirudin in the
urrent study, there seems little question that bivalirudin
ould be reasonably cost-effective compared with heparin as
ell.
Given its lower cost and similar outcomes compared with
eparin routine GP IIb/IIIa inhibition, it is reasonable to
uestion whether bivalirudin  provisional GP IIb/IIIa
nhibition should be considered an economically dominant
nticoagulation regimen for contemporary PCI. However,
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November 2, 2004:1792–800 Cost-Effectiveness of Bivalirudin for PCIn light of the design of the current study, some caution is
arranted in interpreting these results. Although formal
tatistical analysis demonstrated non-inferiority based on
he primary results of the REPLACE-2 trial, these calcu-
ations were based on a combination of regulatory consid-
rations and clinical insight. Indeed, modest increases in
verall costs (such as those observed with routine GP
Ib/IIIa inhibition in this trial) might still be acceptable if
ong-term survival were, in fact, improved. At present,
owever, there is little evidence to support this assumption.
n fact, both 30-day (0.2% vs. 0.4%, p 0.26) and one-year
1.9% vs. 2.6%, p  0.15) mortality rates from the
EPLACE-2 trial tended to favor the bivalirudin group
17).
Moreover, recent studies have suggested that for patients
t very low risk of ischemic complications, a combination of
igh-dose heparin  600 mg of clopidogrel may yield
imilar rates of ischemic complications as low-dose heparin
GP IIb/IIIa inhibition (18). In light of these findings, it
s unclear whether bivalirudin  provisional GP IIb/IIIa
nhibition would offer economic or clinical advantages for
hese low-risk populations. Further studies with adequate
tatistical power to demonstrate modest differences in isch-
mic complication rates are an essential first step to resolve
his issue.
tudy limitations. Several limitations of our study are
orth noting. We did not collect primary cost data on all
tudy participants. Given the size and scope of the trial, we
elt that such an effort would have been relatively inefficient.
nstead, we elected to collect primary cost data on a large
ubset of patients (2,500) selected at random, including all
atients who experienced a major complication. As a result,
ur imputation model was highly predictive (R2 0.74) and
table over a broad range of alternative sampling scenarios.
econd, the time frame encompassed by our analysis was
elatively brief. Because six-month rates of target vessel
evascularization did not differ between the two treatment
roups in the current study (17), however, it is unlikely that
onger-term follow-up would have improved our estimation
f the relevant cost differences.
Third, the heparin dose selected for our study (65 U/kg)
as slightly higher than the dose previously studied in the
nhanced Suppression of the Platelet IIb/IIIa Receptor
ith Integrilin Therapy (ESPRIT) trial (60 U/kg) (3).
hether use of a lower heparin dose would have mitigated
he excess bleeding events seen in the heparin  GP
Ib/IIIa arm of the REPLACE-2 trial with no loss of
fficacy is purely speculative, however. Fourth, the results of
ur economic analysis apply only to those patients who were
ctually studied in the REPLACE-2 trial. Because patients
ith ongoing acute MI or high-risk acute coronary syn-
romes receiving GP IIb/IIIa inhibition before PCI were
xcluded by protocol, our findings should not be extrapo-
ated to these specific populations.
Finally, it is likely that we have underestimated the extent
f cost savings that might ultimately be achieved by biva-irudin in contemporary PCI. In particular, it is possible that
he design of the REPLACE-2 trial artificially increased
ospital costs for the bivalirudin group. The mean infusion
uration for bivalirudin was 44 min, compared with 12 h for
bciximab and 18 h for eptifibatide. Nonetheless, as a
ouble-blind trial, all patients in the bivalirudin group
eceived 12 to 18 h of a placebo infusion, thus eliminating
n important opportunity to streamline care and reduce
ost. Outpatient PCI is rarely performed in U.S. today, in
art because of the need for extended infusions of antiplate-
et agents as well as lower reimbursement levels compared
ith inpatient procedures. Given its brief infusion duration
nd enhanced safety profile, bivalirudin with provisional GP
Ib/IIIa inhibition might lead to substantial additional
avings in the future by facilitating PCI in the outpatient
etting.
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